99 related articles for article (PubMed ID: 2696307)
1. Potency classification of topical corticosteroids: modern perspectives.
Ashworth J
Acta Derm Venereol Suppl (Stockh); 1989; 151():20-5; discussion 47-52. PubMed ID: 2696307
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometrically-sorted residual HLA-DR+T6+ Langerhans cells in topical steroid-treated human skin express normal amounts of HLA-DR and CD1a/T6 antigens and exhibit normal alloantigen-presenting capacity.
Ashworth J; Kahan MC; Breathnach SM
J Invest Dermatol; 1989 Feb; 92(2):258-62. PubMed ID: 2783952
[TBL] [Abstract][Full Text] [Related]
3. Topical application of potent glucocorticoids augments epidermal beta-adrenergic adenylate cyclase response in vivo.
Kajita S; Iizuka H; Hirokawa M; Tsutsui M; Mizumoto T
Acta Derm Venereol; 1986; 66(6):491-6. PubMed ID: 2433868
[TBL] [Abstract][Full Text] [Related]
4. Effects of topical corticosteroid therapy on Langerhans cell antigen presenting function in human skin.
Ashworth J; Booker J; Breathnach SM
Br J Dermatol; 1988 Apr; 118(4):457-69. PubMed ID: 3288268
[TBL] [Abstract][Full Text] [Related]
5. Epidermal cell DNA content and intermediate filaments keratin 10 and vimentin after treatment of psoriasis with calcipotriol cream once daily, twice daily and in combination with clobetasone 17-butyrate cream or betamethasone 17-valerate cream: a comparative flow cytometric study.
Glade CP; Van Erp PE; Van De Kerkhof PC
Br J Dermatol; 1996 Sep; 135(3):379-84. PubMed ID: 8949429
[TBL] [Abstract][Full Text] [Related]
6. Removal of the majority of epidermal Langerhans cells by topical or systemic steroid application enhances the effector phase of murine contact hypersensitivity.
Grabbe S; Steinbrink K; Steinert M; Luger TA; Schwarz T
J Immunol; 1995 Nov; 155(9):4207-17. PubMed ID: 7594576
[TBL] [Abstract][Full Text] [Related]
7. Effect of glucocorticosteroids on epidermal Langerhans cells.
Belsito DV; Flotte TJ; Lim HW; Baer RL; Thorbecke GJ; Gigli I
J Exp Med; 1982 Jan; 155(1):291-302. PubMed ID: 6459400
[TBL] [Abstract][Full Text] [Related]
8. Effects of physicochemical agents on murine epidermal Langerhans cells and Thy-1-positive dendritic epidermal cells.
Aberer W; Romani N; Elbe A; Stingl G
J Immunol; 1986 Feb; 136(4):1210-6. PubMed ID: 2868057
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent effect of topical corticosteroids on blood flow in human cutaneous tissue.
Kristensen JK; Wadskov S; Henriksen O
Acta Derm Venereol; 1978; 58(2):145-8. PubMed ID: 76394
[TBL] [Abstract][Full Text] [Related]
10. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506).
Panhans-Gross A; Novak N; Kraft S; Bieber T
J Allergy Clin Immunol; 2001 Feb; 107(2):345-52. PubMed ID: 11174203
[TBL] [Abstract][Full Text] [Related]
11. Effects of occlusive tape systems on the mitotic activity of epidermis. With and without corticosteroids.
Fisher LB; Maibach HI; Trancik RJ
Arch Dermatol; 1978 Mar; 114(3):384-6. PubMed ID: 629573
[TBL] [Abstract][Full Text] [Related]
12. PUVA therapy decreases HLA-DR+ CDIa+ Langerhans cells and epidermal cell antigen-presenting capacity in human skin, but flow cytometrically-sorted residual HLA-DR+ CDIa+ Langerhans cells exhibit normal alloantigen-presenting function.
Ashworth J; Kahan MC; Breathnach SM
Br J Dermatol; 1989 Mar; 120(3):329-39. PubMed ID: 2469456
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis.
Schuller E; Oppel T; Bornhövd E; Wetzel S; Wollenberg A
J Allergy Clin Immunol; 2004 Jul; 114(1):137-43. PubMed ID: 15241357
[TBL] [Abstract][Full Text] [Related]
14. Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.
Borelli C; Gassmueller J; Fluhr JW; Nietsch KH; Schinzel S; Korting HC
Skin Pharmacol Physiol; 2008; 21(3):181-7. PubMed ID: 18523415
[TBL] [Abstract][Full Text] [Related]
15. Topical corticosteroids.
Med Lett Drugs Ther; 1991 Nov; 33(857):108-10. PubMed ID: 1943979
[No Abstract] [Full Text] [Related]
16. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
Meyer E; Smith EW; Haigh JM; Kanfer I
Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
[TBL] [Abstract][Full Text] [Related]
17. In vivo treatment with anti-I-A antibodies: differential effects on Ia antigens and antigen-presenting cell function of spleen cells and epidermal Langerhans cells.
Aberer W; Kruisbeek AM; Shimada S; Katz SI
J Immunol; 1986 Feb; 136(3):830-6. PubMed ID: 3455705
[TBL] [Abstract][Full Text] [Related]
18. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy.
McMichael AJ; Griffiths CE; Talwar HS; Finkel LJ; Rafal ES; Hamilton TA; Voorhees JJ
Br J Dermatol; 1996 Jul; 135(1):60-4. PubMed ID: 8776360
[TBL] [Abstract][Full Text] [Related]
19. Topical retinoic acid does not alter the vasoconstrictive properties of topical corticosteroids in humans.
Schmied C; Saurat JH
Dermatologica; 1991; 182(2):107-11. PubMed ID: 2050230
[TBL] [Abstract][Full Text] [Related]
20. Novel predictive assay for contact allergens using human skin explant cultures.
Pistoor FH; Rambukkana A; Kroezen M; Lepoittevin JP; Bos JD; Kapsenberg ML; Das PK
Am J Pathol; 1996 Jul; 149(1):337-43. PubMed ID: 8686758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
